首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1801391

脊髓灰质炎疫苗市场报告：2031 年趋势、预测与竞争分析

Poliomyelitis Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年08月29日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

全球脊髓灰质炎疫苗市场前景光明，疫苗接种相关疫苗 (VAPP) 和疫苗衍生小儿麻痹疫苗 (VDPV) 市场蕴藏着机会。预计2025年至2031年期间，全球脊髓灰质炎疫苗市场的复合年增长率将达到2.3%。市场的主要驱动力包括：疫苗接种意识的提升、常规疫苗接种需求的增加，以及政府和机构的大力资金投入和支持。

Lucintel 预测，随着对易于管理、无针免疫接种方式的需求不断增加，口服脊髓灰质炎疫苗的使用将推动脊髓灰质炎在预测期内实现高速成长。
从应用来看，由于人们对 VDPV 疫情的担忧日益加剧，预计 VDPV 将出现高速成长，这推动了对有针对性的疫苗接种策略的需求。
按地区划分，预计北美在预测期内将经历最高的成长。

脊髓灰质炎疫苗市场的新趋势

全球脊髓灰质炎疫苗市场瞬息万变，疫苗配方、分发和免疫接种计画面临新的挑战和机会。近期趋势主要集中在持续努力根除脊髓灰质炎、扩大疫苗在被忽视地区的覆盖范围以及应对疫苗衍生脊髓灰质炎病毒疫情。以下是影响全球脊髓灰质炎疫苗市场的五大新兴趋势。

灭活脊髓灰质炎疫苗自动化程度不断提升：随着疫苗衍生脊髓灰质炎(VDPV) 指示病例在世界各地拉响警报，大多数国家正在从口服脊髓灰质炎疫苗 (OPV) 过渡到灭活小儿麻痹疫苗 (IPV)。 IPV 能够在维持免疫力的同时消除 VDPV 的风险，使其成为确保根除脊髓灰质炎的关键组成部分。这项过渡在免疫覆盖率低和医疗基础设施薄弱的地区尤为关键。 IPV 的全球市场正在不断扩大，因为它能够安全、长期地维持对脊髓灰质炎的免疫力，同时最大限度地降低脊髓灰质炎復发的可能性。
加强监测和监控：随着全球根除脊髓灰质炎的目标日益临近，加强监测系统以发现和监控脊髓灰质炎传播的需求日益增加。监测不仅包括病毒基因组成，还包括改善事件报告和追踪疫苗接种覆盖率。对于那些多年来已无脊髓灰质炎、但由于疫苗接种率低或移民人数众多而面临风险的国家，监测也至关重要。加强监测对于及早发现疫情并早期疗育以阻止感染蔓延至关重要。
将疫苗接种工作与其他国家策略相协调：一些国家正在采用这项策略来提高脊髓灰质炎疫苗接种覆盖率，同时降低营运成本。此类综合方法旨在透过将脊髓灰质炎疫苗接种与麻疹和乙肝疫苗接种相结合，或透过提高常规疫苗对有需要儿童的可及性来提高覆盖率。这在低收入和偏远地区（医疗机构较远）变得越来越重要。将儿童纳入现有计画也有助于改善整体免疫接种和公共卫生体系。
新型脊髓灰质炎疫苗的研发：新型联合疫苗和改良剂型正在研发中。这些疫苗可能能够增强免疫反应，促进疫苗递送，并提高运输和储存所需的稳定性。此外，针对儿童疫苗（包括脊髓灰质炎与其他疫苗的合併使用）的新型佐剂和递送系统也正在研发中。这些创新可能提供更好的选择，尤其是在后勤受限或疫情模式正在显现的地区。
私部门和官民合作关係：私人企业正越来越多地参与全球脊髓灰质炎免疫宣传活动，製药公司也投资于疫苗的生产、行销和研发。官民合作关係关係是对脊髓灰质炎根除策略的有效补充，尤其是在资源匮乏的地区。这些合作支持中低收入国家建立疫苗储备并进行定价，从而加强全球脊髓灰质炎根除工作。

随着世界朝着根除脊髓灰质炎的目标快速迈进，全球脊髓灰质炎疫苗市场出现了一些新兴趋势，例如使用小儿麻痹疫苗（IPV）、加强监测以及将疫苗纳入免疫计划，这些趋势在市场上得到了强烈的体现。这些趋势正在增加疫苗的可得性，增强脊髓灰质炎疫苗的安全性，并提高全球管理效率。此外，新型疫苗的出现和发展，以及官民合作关係关係，正在帮助克服大规模免疫宣传活动中的后勤和资金限制。

脊髓灰质炎疫苗市场的最新趋势

全球脊髓灰质炎疫苗市场的最新变化是经过深思熟虑的，重点关注对全球根除脊髓灰质炎宣传活动成功至关重要的因素，包括引入小儿麻痹加强剂、生产创新、分销创新以及国际合作。脊髓灰质炎免疫策略的发展进展将提高免疫覆盖率，并将非代表性族群纳入其中，有助于实现全球根除脊髓灰质炎和消除疫苗衍生株的最终目标。以下是塑造全球脊髓灰质炎疫苗市场未来的五个关键发展。

全球从口服脊髓灰质炎疫苗 (OPV) 向灭活小儿麻痹疫苗 (IPV) 过渡：全球从口服小儿麻痹疫苗 (OPV) 向灭活脊髓灰质炎疫苗 (IPV) 过渡是脊髓灰质炎疫苗市场的重大变革之一。 IPV 消除了疫苗相关脊髓灰质炎(VAP) 的风险，而这正是 OPV 面临的挑战。世界卫生组织 (WHO) 和其他卫生组织倡导这一转变，以安全地增强免疫力。 IPV 已被纳入国家免疫接种计划，以确保全球根除小儿麻痹宣传活动顺利推进。
在常规免疫接种计划中，IPV 的使用有所改善：印度和中国等国家已将 IPV 纳入其常规免疫计划，以帮助其对抗脊髓灰质炎。在根除小儿麻痹的最后阶段，将 IPV 与 OPV 合併使用，有助于维持人群免疫力，同时又不会增加 VDPV 疫情的威胁。这两种方法相辅相成，加强了免疫宣传活动，并有助于预防脊髓灰质炎復发。
加强监测：透过更严格的监测系统，脊髓灰质炎传播正得到有效控制。脊髓灰质炎基因定序、改进的报告系统和即时资讯对于及早发现疫情至关重要。这些进展使得快速反应成为可能，尤其是在受影响国家，并使疫苗接种能够尽快进行。这有助于确保不遗漏任何新的脊髓灰质炎病例，并为根除脊髓灰质炎的最后衝刺提供强有力的支持。
加大全球对根除脊髓灰质炎工作的投入：世界卫生组织、各国政府和私人机构为全球根除脊髓灰质炎行动（GPEI）等计划提供了大量资金支持。这些投入促进了疫苗宣传活动和接种工作，即使在疫苗匮乏和受衝突影响的地区也是如此。卫生基础设施的加强和资金支持为免疫接种计画的成功做出了重要贡献，使脊髓灰质炎始终成为全球卫生的焦点。
官民合作关係促进疫苗可及性：葛兰素史克和赛诺菲等公司正与国际卫生组织合作，在众多低收入和服务欠缺地区扩大脊髓灰质炎疫苗的可及性，发挥着至关重要的作用。这项工作旨在克服高成本、物流挑战和医疗服务不足等障碍，使更多国家能够获得疫苗。此类合作有助于发展疫苗库存，改善疫苗分发，并扩大全球疫苗生产规模。

全球脊髓灰质炎疫苗市场的最新发展凸显了过渡、监测、资金筹措和合作在对抗脊髓灰质炎中的重要性。支持接种小儿麻痹疫苗（IPV）、改善监测以及公私合营正在加强全球疫苗接种工作。这些努力，加上应对疫苗相关挑战和疫情，正在使世界更接近根除脊髓灰质炎的目标。目前，市场正致力于在世界各地实施持续的疫苗接种和监测项目，以确保根除脊髓灰质炎的目标仍然可行。

The future of the global poliomyelitis vaccine market looks promising with opportunities in the VAPP, VDPV markets. The global poliomyelitis vaccine market is expected to grow with a CAGR of 2.3% from 2025 to 2031. The major drivers for this market are the growing awareness about immunization and the need for routine vaccinations, and the strong funding and support from governments and organizations.

Lucintel forecasts that, within the type category, the oral poliomyelitis vaccine is expected to witness higher growth over the forecast period due to the growing demand for easy-to-administer and needle-free vaccination options, which is boosting oral polio vaccine use.
Within the application category, VDPV is expected to witness higher growth due to rising concerns over VDPV outbreaks, which are driving demand for targeted vaccination strategies.
In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market is constantly changing as there are new challenges and new opportunities when it comes to vaccine formulation, distribution, and immunization plans. The recent trends are targeting the perpetual efforts to eradicate polio, widening the scope of available vaccines in neglected areas, and addressing the problems of outbreaks of vaccine-derived poliovirus. Below are five emerging trends that are persistent in the shaping of the global poliomyelitis vaccine market.

Increasing automation of the inactivated polio vaccine: As the vaccine-derived poliovirus (VDPV) index cases have raised alarm bells around the world, most countries are transitioning from oral polio vaccine (OPV) to IPV. IPV also removes the VDPV risk but preserves immunity, which remains critical in ensuring that polio eradication is achieved. This transition is most relevant in regions with poor immunization rates and weak healthcare infrastructure. The world market for IPV is expanding owing to its ability to provide safe and long-term immunity against polio with minimal chances of another outbreak.
Growing emphasis on surveillance and monitoring: With the goal of eradicating polio from the entire globe, there is an increasing need to strengthen the surveillance system to detect and monitor poliovirus transmission. Surveillance includes not only the genetic makeup of the virus but also improvements in the reporting of events and tracking vaccination coverage. Surveillance is vital even for countries that have already been polio-free for years but pose risks due to low vaccination coverage or migration patterns. These enhancements are critical for the early detection of outbreaks and limiting potential spread through early interventions.
Vaccination deliveries linked with other national strategies: Some countries are using this strategy to improve the coverage of polio vaccination while at the same time reducing operational expenditures. Such integrated approaches target increased coverage by interspersing polio vaccinations with measles or hepatitis B and improving the availability of various routine vaccines to children, which would otherwise go unvaccinated. This is becoming a more crucial trend in low-income and hard-to-reach areas where distances to healthcare facilities are vast. Integrating children into available programs also improves the general immunization system and the public health systems.
Development of new types of polio vaccines: Novel combination vaccines and improved formulations are under development. These vaccines are expected to improve the immune response, ease vaccine delivery, and improve stability features required for transport and storage. New adjuvants or delivery systems, as well as combined vaccines, e.g., polio with other vaccines administered to children, are being investigated. Such innovations may offer better options, especially in areas that have logistical constraints or where there are new patterns of outbreaks.
Private sector and public-private partnerships: Participation of the private sector in the global polio vaccination campaign has risen, with pharmaceutical companies investing towards vaccine manufacturing, marketing, and research. Public-private partnerships are effective in complementing polio eradication strategies, particularly in resource-constrained settings. Such collaborations assist in developing vaccine stocks and pricing for lower- and middle-income countries, thus enhancing global polio eradication efforts.

As the world moves rapidly towards the goal of eradicating polio, trends such as the usage of IPV, improved issues on surveillance, or the streamlining of vaccines with immunization programs are strong emerging trends in the global poliomyelitis vaccine market. These trends are enhancing the availability of vaccines, increasing the safety of polio vaccines, and improving the efficiency of administration worldwide. And, as in the case of public-private partnerships, new types of vaccines and their development are helping to overcome logistical and financial constraints on wide-scale immunization campaigns.

Recent Developments in the Poliomyelitis Vaccine Market

The latest changes in the global poliomyelitis vaccine market are purposeful, as they draw attention to factors such as the introduction of an IPV booster dose, production innovations, distribution innovations, and international cooperation, which are crucial for the global success of the polio eradication campaign. Progress in the development of polio vaccination strategies contributes to the targeted end goal, which is the global eradication of polio and elimination of vaccine-derived strains, increasing vaccination coverage, and including non-represented people. Below are five key developments shaping the future of the global poliomyelitis vaccine market.

Global move from OPV usage towards IPV: The global movement from the use of oral polio vaccine (OPV) to inactivated polio vaccine (IPV) is one of the major changes in the poliomyelitis vaccine market. With IPV, countries do not have the risk of vaccine-associated poliovirus (VAP), which was a challenge with OPV in some settings. This change is advocated by WHO and other health organizations to enhance immunity safely. IPV doses are incorporated into national immunization schedules to keep the objectives of the global eradication campaign on track.
IPV use improved in routine immunization schedules: Countries like India, China, and others have already incorporated IPV into their routine vaccination programs, aiding in the fight against polio. The use of IPV with OPV during the last stages of eradication has helped maintain population immunity without heightening the threat of VDPV outbreaks. The two approaches supplement each other and help enhance vaccination campaigns, preventing re-emergence of polio.
Enhanced systems of surveillance: The transmission of polio has been effectively controlled through stricter surveillance systems. Polio virus strain genetic sequencing, improved reporting systems, and real-time information have become indispensable for early detection of outbreaks. Such advancements allow for rapid response measures, especially in countries where outbreaks have occurred, ensuring that immunization takes place as quickly as possible. This guarantees that no new cases of polio are missed and strengthens the final push to end the disease.
Greater contributions worldwide for polio eradication efforts: Significant funding from global health organizations, governments, and private entities has been received, notably supporting projects like the Global Polio Eradication Initiative (GPEI). These investments facilitate vaccine marketing campaigns and administration, even in rare and conflict-hit areas. Reinforcing health infrastructure and financial backing has significantly contributed to the success of vaccination programs and kept polio as a focus in global health.
Public-private partnerships for accessible vaccines: Companies like GSK, Sanofi, and others working with international health organizations have played a key role by making polio vaccines available and affordable in many low-income and underserved areas. Efforts aim to make vaccine access possible in more countries by overcoming barriers such as high costs, logistical issues, and inadequate healthcare provision. Such collaborations help develop vaccine stocks, improve distribution, and expand global vaccine manufacturing activities.

Recent developments in the global poliomyelitis vaccine market highlight the importance of transitions, surveillance, funding, and collaborations in the fight against polio. Support for IPV introduction, improved surveillance, and public-private partnerships have enhanced the global push for vaccination. These efforts, combined with addressing vaccine-related challenges and outbreaks, are bringing the world closer to the elimination of polio. The market now focuses on ensuring that polio remains eradicated through sustained immunization and surveillance programs worldwide.

Strategic Growth Opportunities in the Poliomyelitis Vaccine Market

The world's poliomyelitis vaccine market is experiencing acceleration in development owing to challenges posed to polio eradication: mass vaccinations, improvements in vaccine development and dissemination, global cooperation, etc. Now that polio has been eradicated in most places, the challenge is to eliminate this disease entirely and focus on new challenges. The market is still developing and offers possibilities for new strategies in producing, distributing, and monitoring vaccines. In particular, with most countries switching from the oral form of the polio vaccine to the inactivated type, here are five growth opportunities that will cut across sectors in the poliomyelitis vaccine market.

Increasing usage of IPV within routine immunization schedules: The transition from OPV to IPV brings potential for increased revenue. IPV offers enhanced safety as residual VDPV is absent. Continued use of IPV in countries that have achieved polio-free status will help protect against resurgence. This change necessitates increased capacity in vaccine manufacturing, cold chain logistics, and regulatory frameworks, providing growth avenues for manufacturers and health organizations.
The use of combination vaccines to eradicate polio circulation: Including polio vaccines in DTP (diphtheria, tetanus, pertussis) vaccines enhances the market. Combining polio vaccination with wider immunization activities lowers operational costs and raises coverage. This strategy stimulates demand for combination vaccines, which is cost-effective for manufacturers and health agencies aiming to immunize every child.
Opportunities and constraints regarding polio surveillance and monitoring technologies: Advanced surveillance technology is critical for global eradication, offering opportunities in genomic surveillance, diagnostic technologies, handheld health devices, and real-time reporting systems. Reinforcing surveillance networks is especially important in weak health system areas or where polio is still endemic. This creates opportunities for diagnostic testing services and data analysis.
Polio vaccine manufacturing and supply chain improvements: The increasing demand for vaccines creates growth opportunities for manufacturing and distribution. Improving vaccine formulation and supply chain management is critical for consistent supply, especially in remote or conflict-affected regions. Collaboration between public health agencies and private companies will enhance market profitability and effectiveness.
Public-private partnerships for polio eradication: PPPs have become effective in increasing vaccination coverage in underserved regions. These partnerships enable increased funding, resource sharing, and expertise, helping to overcome geographical and financial barriers. Securing investments through these partnerships enhances rapid deployment, infrastructure development, and manufacturing expansion.

The scenario of the poliomyelitis vaccine market globally looks favorable, with several growth opportunities such as vaccine proliferation, collaboration with other vaccine programs, technology integration for surveillance, improved manufacturing processes, and public-private partnerships. These opportunities support efforts to achieve polio eradication and sustained immunity in the post-eradication period. Synergistic actions between manufacturers, international health bodies, and governments are essential for enhancing vaccination, supply chain management, and surveillance.

Poliomyelitis Vaccine Market Driver and Challenges

There are many factors affecting the global market of poliomyelitis vaccines, including technological innovations, economic factors, and regulations. These factors influence vaccine purchase, vaccination processes, and the effectiveness of global eradication efforts. However, there are setbacks such as vaccine-derived poliovirus outbreaks, logistical issues, and regional heterogeneity in immunization, which remain challenges. It is important to assess and understand the factors driving and restraining the poliomyelitis vaccine market to succeed.

The factors responsible for driving the Poliomyelitis Vaccine market include:

1. Global campaigns for polio eradication: Led by the Global Polio Eradication Initiative (GPEI), involving WHO, UNICEF, and the Rotary Foundation, supported by substantial funding and political will, improving vaccination levels and supply, and establishing demand for OPV and IPV.

2. Shift toward IPV: The transition from OPV to IPV in immunization programs, especially in polio-free countries, to address VDPV concerns, increasing demand for IPV vaccines.

3. Technological advancements in vaccine production: Innovations such as recombinant DNA, adjuvants, and new formulations reduce costs and increase vaccine availability, especially in poor and conflict-affected regions.

4. Enhanced vaccine availability in developing economies: Initiatives like GAVI make vaccines accessible at reasonable prices, helping restore coverage in endemic areas.

5. Global networking and financial support: International funding and sponsorship support ongoing vaccination, research, and health system strengthening.

Challenges include:

1. Vaccine-derived poliovirus (VDPV): Outbreaks of VDPV, especially with OPV, pose a major obstacle. WHO advocates for IPV to eliminate this risk, but high costs and logistical issues hinder widespread adoption.

2. Logistical challenges: Distribution issues in rural and conflict zones, cold chain problems, wastage, and transportation hurdles.

3. Political conditions and conflict zones: Ongoing violence and conflict, especially in Afghanistan and Pakistan, hinder vaccination efforts.

International cooperation, improved mechanisms, and persistent efforts are necessary to eradicate poliomyelitis globally. Addressing challenges like VDPV, logistics, and socio-political issues is crucial for effective immunization programs.

List of Poliomyelitis Vaccine Companies

Companies in the market compete based on product quality. Major players focus on expanding manufacturing, R&D, infrastructure, and leveraging integration across the value chain. These strategies help cater to increasing demand, develop innovative products, reduce costs, and expand customer bases. Some of the companies profiled include:

GSK
Sanofi-Pasteur
Merck
Crucell
China National Biotech Group

Poliomyelitis Vaccine Market by Segment

The study includes a forecast for the global poliomyelitis vaccine market by type, application, and region.

Poliomyelitis Vaccine Market by Type [Value from 2019 to 2031]:

Poliomyelitis Vaccine I
Poliomyelitis Vaccine II
Poliomyelitis Vaccine III
Oral Poliomyelitis Vaccine

Poliomyelitis Vaccine Market by Application [Value from 2019 to 2031]:

VAPP
VDPV

Poliomyelitis Vaccine Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market has been a concern for numerous decades. The highly contagious disease, if left unmanaged, can lead to death or paralysis. Efforts to eliminate the disease have been mostly successful owing to advancements in polio vaccines. In countries such as the USA, China, Germany, India, and Japan, recent advancements focus on expanding vaccine distribution, managing outbreaks, and providing assistance with the last phase of elimination. Improvements in diffusion methods and timing, localized educational programs, and closer collaboration between global health agencies are expected to advance vaccination efforts in these areas.

United States: Despite being at the forefront of polio vaccination and eradication efforts, occasional outbreaks from vaccine strains occur due to OPV. Prevention strategies include promoting IPV use. The CDC has expanded surveillance systems, ensured robust vaccination programs, and supports global eradication efforts. Maintaining polio-free certification through continuous investments and immunity is paramount.
China: China has made significant progress in combating poliomyelitis, switching from OPV to IPV in 2016. Efforts include enhancing immunization systems, routine vaccination coverage, and vaccine supply chain management. China collaborates with WHO and other organizations, though challenges remain in large rural populations and migration.
Germany: Germany remains a key player in global polio eradication, vaccinating with IPV only, maintaining high coverage, and participating in campaigns like GPEI. The country emphasizes awareness among migrants to ensure access to vaccination. Its strong healthcare system supports these efforts.
India: India was declared polio-free in 2014 after decades of vaccination campaigns. Current efforts focus on maintaining this status and increasing immunization coverage, especially among marginalized and rural communities, with active government involvement.
Japan: Japan has maintained excellent polio vaccination coverage for decades, employing IPV-only strategies. It supports international campaigns and has strengthened its health system to prevent reintroduction, serving as a leader in global health.

Features of the Global Poliomyelitis Vaccine Market

Market Size Estimates: Estimation of market size in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by segments and regions.
Segmentation Analysis: Market size by type, application, and region in dollar value.
Regional Analysis: Breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities across types, applications, and regions.
Strategic Analysis: Includes M&A, new product development, and competitive landscape.

Industry competitiveness based on Porter's Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the poliomyelitis vaccine market by type (poliomyelitis vaccine I, II, III, and oral poliomyelitis vaccine), application (VAPP and VDPV), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Poliomyelitis Vaccine Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Poliomyelitis Vaccine I: Trends and Forecast (2019-2031)
4.4 Poliomyelitis Vaccine II: Trends and Forecast (2019-2031)
4.5 Poliomyelitis Vaccine III: Trends and Forecast (2019-2031)
4.6 Oral Poliomyelitis Vaccine: Trends and Forecast (2019-2031)

5. Global Poliomyelitis Vaccine Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 VAPP: Trends and Forecast (2019-2031)
5.4 VDPV: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Poliomyelitis Vaccine Market by Region

7. North American Poliomyelitis Vaccine Market

7.1 Overview
7.2 North American Poliomyelitis Vaccine Market by Type
7.3 North American Poliomyelitis Vaccine Market by Application
7.4 United States Poliomyelitis Vaccine Market
7.5 Mexican Poliomyelitis Vaccine Market
7.6 Canadian Poliomyelitis Vaccine Market

8. European Poliomyelitis Vaccine Market

8.1 Overview
8.2 European Poliomyelitis Vaccine Market by Type
8.3 European Poliomyelitis Vaccine Market by Application
8.4 German Poliomyelitis Vaccine Market
8.5 French Poliomyelitis Vaccine Market
8.6 Spanish Poliomyelitis Vaccine Market
8.7 Italian Poliomyelitis Vaccine Market
8.8 United Kingdom Poliomyelitis Vaccine Market

9. APAC Poliomyelitis Vaccine Market

9.1 Overview
9.2 APAC Poliomyelitis Vaccine Market by Type
9.3 APAC Poliomyelitis Vaccine Market by Application
9.4 Japanese Poliomyelitis Vaccine Market
9.5 Indian Poliomyelitis Vaccine Market
9.6 Chinese Poliomyelitis Vaccine Market
9.7 South Korean Poliomyelitis Vaccine Market
9.8 Indonesian Poliomyelitis Vaccine Market

10. ROW Poliomyelitis Vaccine Market

10.1 Overview
10.2 ROW Poliomyelitis Vaccine Market by Type
10.3 ROW Poliomyelitis Vaccine Market by Application
10.4 Middle Eastern Poliomyelitis Vaccine Market
10.5 South American Poliomyelitis Vaccine Market
10.6 African Poliomyelitis Vaccine Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Poliomyelitis Vaccine Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 GSK
- Company Overview
- Poliomyelitis Vaccine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Sanofi-Pasteur
- Company Overview
- Poliomyelitis Vaccine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Merck
- Company Overview
- Poliomyelitis Vaccine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Crucell
- Company Overview
- Poliomyelitis Vaccine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 China National Biotech Group
- Company Overview
- Poliomyelitis Vaccine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global Poliomyelitis Vaccine Market
Figure 2.1: Usage of Poliomyelitis Vaccine Market
Figure 2.2: Classification of the Global Poliomyelitis Vaccine Market
Figure 2.3: Supply Chain of the Global Poliomyelitis Vaccine Market
Figure 2.4: Driver and Challenges of the Poliomyelitis Vaccine Market
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 4.1: Global Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Poliomyelitis Vaccine Market ($B) by Type
Figure 4.3: Forecast for the Global Poliomyelitis Vaccine Market ($B) by Type
Figure 4.4: Trends and Forecast for Poliomyelitis Vaccine I in the Global Poliomyelitis Vaccine Market (2019-2031)
Figure 4.5: Trends and Forecast for Poliomyelitis Vaccine II in the Global Poliomyelitis Vaccine Market (2019-2031)
Figure 4.6: Trends and Forecast for Poliomyelitis Vaccine III in the Global Poliomyelitis Vaccine Market (2019-2031)
Figure 4.7: Trends and Forecast for Oral Poliomyelitis Vaccine in the Global Poliomyelitis Vaccine Market (2019-2031)
Figure 5.1: Global Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Poliomyelitis Vaccine Market ($B) by Application
Figure 5.3: Forecast for the Global Poliomyelitis Vaccine Market ($B) by Application
Figure 5.4: Trends and Forecast for VAPP in the Global Poliomyelitis Vaccine Market (2019-2031)
Figure 5.5: Trends and Forecast for VDPV in the Global Poliomyelitis Vaccine Market (2019-2031)
Figure 6.1: Trends of the Global Poliomyelitis Vaccine Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Poliomyelitis Vaccine Market ($B) by Region (2025-2031)
Figure 7.1: Trends and Forecast for the North American Poliomyelitis Vaccine Market (2019-2031)
Figure 7.2: North American Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
Figure 7.3: Trends of the North American Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
Figure 7.4: Forecast for the North American Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
Figure 7.5: North American Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
Figure 7.6: Trends of the North American Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
Figure 7.7: Forecast for the North American Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
Figure 7.8: Trends and Forecast for the United States Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Mexican Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 7.10: Trends and Forecast for the Canadian Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 8.1: Trends and Forecast for the European Poliomyelitis Vaccine Market (2019-2031)
Figure 8.2: European Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
Figure 8.3: Trends of the European Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
Figure 8.4: Forecast for the European Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
Figure 8.5: European Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
Figure 8.6: Trends of the European Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
Figure 8.7: Forecast for the European Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
Figure 8.8: Trends and Forecast for the German Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the French Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Spanish Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the Italian Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 8.12: Trends and Forecast for the United Kingdom Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 9.1: Trends and Forecast for the APAC Poliomyelitis Vaccine Market (2019-2031)
Figure 9.2: APAC Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
Figure 9.3: Trends of the APAC Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
Figure 9.4: Forecast for the APAC Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
Figure 9.5: APAC Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
Figure 9.6: Trends of the APAC Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
Figure 9.7: Forecast for the APAC Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
Figure 9.8: Trends and Forecast for the Japanese Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Indian Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the Chinese Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the South Korean Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 9.12: Trends and Forecast for the Indonesian Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 10.1: Trends and Forecast for the ROW Poliomyelitis Vaccine Market (2019-2031)
Figure 10.2: ROW Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
Figure 10.3: Trends of the ROW Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
Figure 10.4: Forecast for the ROW Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
Figure 10.5: ROW Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
Figure 10.6: Trends of the ROW Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
Figure 10.7: Forecast for the ROW Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
Figure 10.8: Trends and Forecast for the Middle Eastern Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the South American Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 10.10: Trends and Forecast for the African Poliomyelitis Vaccine Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Poliomyelitis Vaccine Market
Figure 11.2: Market Share (%) of Top Players in the Global Poliomyelitis Vaccine Market (2024)
Figure 12.1: Growth Opportunities for the Global Poliomyelitis Vaccine Market by Type
Figure 12.2: Growth Opportunities for the Global Poliomyelitis Vaccine Market by Application
Figure 12.3: Growth Opportunities for the Global Poliomyelitis Vaccine Market by Region
Figure 12.4: Emerging Trends in the Global Poliomyelitis Vaccine Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Poliomyelitis Vaccine Market by Type and Application
Table 1.2: Attractiveness Analysis for the Poliomyelitis Vaccine Market by Region
Table 1.3: Global Poliomyelitis Vaccine Market Parameters and Attributes
Table 3.1: Trends of the Global Poliomyelitis Vaccine Market (2019-2024)
Table 3.2: Forecast for the Global Poliomyelitis Vaccine Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Poliomyelitis Vaccine Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 4.4: Trends of Poliomyelitis Vaccine I in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 4.5: Forecast for Poliomyelitis Vaccine I in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 4.6: Trends of Poliomyelitis Vaccine II in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 4.7: Forecast for Poliomyelitis Vaccine II in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 4.8: Trends of Poliomyelitis Vaccine III in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 4.9: Forecast for Poliomyelitis Vaccine III in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 4.10: Trends of Oral Poliomyelitis Vaccine in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 4.11: Forecast for Oral Poliomyelitis Vaccine in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Poliomyelitis Vaccine Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 5.4: Trends of VAPP in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 5.5: Forecast for VAPP in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 5.6: Trends of VDPV in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 5.7: Forecast for VDPV in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Poliomyelitis Vaccine Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Poliomyelitis Vaccine Market (2025-2031)
Table 7.1: Trends of the North American Poliomyelitis Vaccine Market (2019-2024)
Table 7.2: Forecast for the North American Poliomyelitis Vaccine Market (2025-2031)
Table 7.3: Market Size and CAGR of Various Type in the North American Poliomyelitis Vaccine Market (2019-2024)
Table 7.4: Market Size and CAGR of Various Type in the North American Poliomyelitis Vaccine Market (2025-2031)
Table 7.5: Market Size and CAGR of Various Application in the North American Poliomyelitis Vaccine Market (2019-2024)
Table 7.6: Market Size and CAGR of Various Application in the North American Poliomyelitis Vaccine Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Poliomyelitis Vaccine Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Poliomyelitis Vaccine Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Poliomyelitis Vaccine Market (2019-2031)
Table 8.1: Trends of the European Poliomyelitis Vaccine Market (2019-2024)
Table 8.2: Forecast for the European Poliomyelitis Vaccine Market (2025-2031)
Table 8.3: Market Size and CAGR of Various Type in the European Poliomyelitis Vaccine Market (2019-2024)
Table 8.4: Market Size and CAGR of Various Type in the European Poliomyelitis Vaccine Market (2025-2031)
Table 8.5: Market Size and CAGR of Various Application in the European Poliomyelitis Vaccine Market (2019-2024)
Table 8.6: Market Size and CAGR of Various Application in the European Poliomyelitis Vaccine Market (2025-2031)
Table 8.7: Trends and Forecast for the German Poliomyelitis Vaccine Market (2019-2031)
Table 8.8: Trends and Forecast for the French Poliomyelitis Vaccine Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Poliomyelitis Vaccine Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Poliomyelitis Vaccine Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Poliomyelitis Vaccine Market (2019-2031)
Table 9.1: Trends of the APAC Poliomyelitis Vaccine Market (2019-2024)
Table 9.2: Forecast for the APAC Poliomyelitis Vaccine Market (2025-2031)
Table 9.3: Market Size and CAGR of Various Type in the APAC Poliomyelitis Vaccine Market (2019-2024)
Table 9.4: Market Size and CAGR of Various Type in the APAC Poliomyelitis Vaccine Market (2025-2031)
Table 9.5: Market Size and CAGR of Various Application in the APAC Poliomyelitis Vaccine Market (2019-2024)
Table 9.6: Market Size and CAGR of Various Application in the APAC Poliomyelitis Vaccine Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Poliomyelitis Vaccine Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Poliomyelitis Vaccine Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Poliomyelitis Vaccine Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Poliomyelitis Vaccine Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Poliomyelitis Vaccine Market (2019-2031)
Table 10.1: Trends of the ROW Poliomyelitis Vaccine Market (2019-2024)
Table 10.2: Forecast for the ROW Poliomyelitis Vaccine Market (2025-2031)
Table 10.3: Market Size and CAGR of Various Type in the ROW Poliomyelitis Vaccine Market (2019-2024)
Table 10.4: Market Size and CAGR of Various Type in the ROW Poliomyelitis Vaccine Market (2025-2031)
Table 10.5: Market Size and CAGR of Various Application in the ROW Poliomyelitis Vaccine Market (2019-2024)
Table 10.6: Market Size and CAGR of Various Application in the ROW Poliomyelitis Vaccine Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Poliomyelitis Vaccine Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Poliomyelitis Vaccine Market (2019-2031)
Table 10.9: Trends and Forecast for the African Poliomyelitis Vaccine Market (2019-2031)
Table 11.1: Product Mapping of Poliomyelitis Vaccine Suppliers Based on Segments
Table 11.2: Operational Integration of Poliomyelitis Vaccine Manufacturers
Table 11.3: Rankings of Suppliers Based on Poliomyelitis Vaccine Revenue
Table 12.1: New Product Launches by Major Poliomyelitis Vaccine Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Poliomyelitis Vaccine Market

02-2729-4219

+886-2-2729-4219

License/价格

脊髓灰质炎疫苗市场报告：2031 年趋势、预测与竞争分析

Poliomyelitis Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章 市场概述

第三章：市场趋势与预测分析

4. 全球脊髓灰质炎疫苗市场（按类型）

5. 全球脊髓灰质炎疫苗市场（依应用）

第六章区域分析

7.北美脊髓灰质炎疫苗市场

8. 欧洲脊髓灰质炎疫苗市场

9. 亚太地区脊髓灰质炎疫苗市场

10. 其他地区（ROW）脊髓灰质炎市场

第十一章 竞争分析

第十二章机会与策略分析

第十三章 价值链主要企业概况

第十四章 附录